免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Pro- and Anti-Tumoral Factors Involved in Total Body Irradiation and Interleukin-2 Conditioning in Adoptive T Cell Therapy of Melanoma-Bearing Rag1 Knock-Out Mice.
Pro- and Anti-Tumoral Factors Involved in Total Body Irradiation and Interleukin-2 Conditioning in Adoptive T Cell Therapy of Melanoma-Bearing Rag1 Knock-Out Mice.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
在过继性T细胞治疗(ACT)中,肿瘤特异性T细胞的转移与预处理方案并行,以提高治疗效果。预处理的目的是清除免疫抑制细胞,而后处理则增加稳态信号以改善输入T细胞的持久性。识别参与预处理方案的有利免疫学因素对于设计有效的ACT策略至关重要。
在此,我们利用小鼠黑色素瘤的ACT模型,评估了全身照射(TBI)与白细胞介素-2(IL-2)联合治疗的效果。使用缺乏内源性T细胞的Rag1敲除株,能够以更聚焦于转移T细胞的方式识别相关因素。
我们证明,尽管每种预处理均能改善治疗结果,但TBI/IL-2联合在ACT中并无叠加效应。虽然联合治疗增加了转移T细胞在淋巴组织和肿瘤组织中的频率,但与单独TBI治疗相比,这些细胞的活化强度降低。
值得注意的是,我们发现在TBI存在的情况下,IL-2治疗降低了瘤内树突状细胞的频率,而树突状细胞对T细胞活化至关重要。本研究为ACT中TBI/IL-2联合所涉及的免疫学事件提供了见解。
In adoptive T cell therapy (ACT), the transfer of tumor-specific T cells is paralleled by the conditioning regimen to increase therapeutic efficacy. Pre-conditioning depletes immune-suppressive cells and post-conditioning increases homeostatic signals to improve the persistence of administered T cells. Identifying the favorable immunological factors involved in a conditioning regimen is important to design effective strategies in ACT.
Here, by using an ACT model of murine melanoma, we evaluate the effect of the total body irradiation (TBI) and interleukin-2 (IL-2) treatment combination. The use of a Rag1 knock-out strain, which lacks endogenous T cells, enables the identification of factors in a way that focuses more on transferred T cells.
We demonstrate that the TBI/IL-2 combination has no additive effect in ACT, although each conditioning improves the therapeutic outcome. While the combination increases the frequency of transferred T cells in lymphoid and tumor tissues, the activation intensity of the cells is reduced compared to that of the sole TBI treatment.
Notably, we show that in the presence of TBI, the IL-2 treatment reduces the frequency of intra-tumoral dendritic cells, which are crucial for T cell activation. The current study provides insights into the immunological events involved in the TBI/IL-2 combination in ACT.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。